Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Syntaxin-binding protein 5 (STXBP5), also known as tomosyn, is a large cytosolic protein that regulates membrane fusion events in exocytosis, primarily by binding syntaxins, which are core components of the SNARE complex. In the nervous system, STXBP5 inhibits synaptic vesicle priming and neurotransmitter release, while in platelets and endothelial cells, it modulates regulated secretion (exocytosis) of granule contents, including von Willebrand factor and P-selectin. Animal studies show that loss of STXBP5 impairs platelet secretion and hemostasis, but increases endothelial exocytosis, highlighting its dual roles. Genetic variations in STXBP5 are associated with altered plasma vWF levels and risk of thrombotic disorders, implicating it as a regulatory factor in cardiovascular disease pathways, although it is not currently a direct therapeutic target[1][2][3][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Syntaxin-binding protein 5 (STXBP5).